Traders News Source Senior Editor, Mark Roberts Interviews Charles Arnold, CEO Stemtech Corporation (OTCQB: STEK)
CHARLES ARNOLD
Chief Executive Officer
Mr. Arnold’s ability to integrate marketing concepts and financial strategies play a pivotal role in the development of his clients’ businesses. In addition to developing start-up companies, he is responsible for placing more than $1 Billion into public companies with as much as $400 Million in a single transaction. Significant mergers and acquisitions have been accomplished through his network of financial specialists and professionals throughout the world. In 1993 Mr. Arnold was one of the original investors in pre-paid legal “PPD” (now Legal Shield). In 2001 he was engaged by Natural Health Trends “LEXXUS” the company grew from under $1.00 to over $40. Traded on the American stock exchange. Mr. Arnold feels that the direct sales marketing is an underserved market that deserves investors’ attention. Mr. Arnold believes that Stemtech has exceptional growth potential and sees this company’s bright future with our innovative stem cell nutrition products and the financial opportunity for our Independent Business Partners.
Over the years, Mr. Arnold has carefully developed worldwide relationships with retail brokerage firms, investment bankers, traders, fund managers, and independent investors. A broad scope of his functions includes public awareness and financial relations campaigns arranged to bring undervalued, little known public companies with significant upside potential to the center of equity markets throughout the world.
For over 35 years, Mr. Arnold traveled extensively serving as a guest speaker for many private and public affairs, including international investment conferences. The investor group’s Mr. Arnold consults have been able to participate in several profitable ventures. Mr. Arnold retired from the lecture circuit 1998. Mr. Arnold was the President and publisher of two financial publications from 1984-1998 (Personal Investing News) a paid circulation of over 500,000 subscribers and (The Sound Money Investor) a geo political Publication with an 80,000 paid circulation. In addition, Mr. Arnold was the host of 4-6 financial conferences a year (Sound Money Investor Conferences). Since 1998 he now concentrates on his primary business, he remains in high demand international as an author and lecturer at seminars on entrepreneurship and business economics and development.
Thank you giving us your time to answer our questions.
Full Interview
Could you give us a brief overview of STEK operations and revenue streams, including subsidiaries?
Stemtech was originally founded in 2005 and is operating under new management since 2018. Stemtech Corporation became a publicly traded company in August 2021 on the OTCQB market under “STEK”, with operations in subsidiary markets in the United Stated States, Canada, Mexico, Ecuador, Taiwan and Malaysia.
STEK has announced its intent to acquire Life Factor Research (LFR), a private company. When do you expect the acquisition to close?
We expect the acquisition to close within ninety (90) days or sooner.
Could you elaborate any synergistic aspects of the acquisition you may have already identified?
Stemtech and Life Factor will be a ‘hand-in-glove’ synergistic impact in that LFR will become the in-house research and development division of Stemtech. LFR will benefit from the existing distribution model of Stemtech plus development of other channels as appropriate and specific to the products developed.
LFR has several interesting conceptual products in development. Does STEK intend to continue the development of most of them and bring them to market, and what might that timeline look like?
Yes, this development will continue and be brought to market via the appropriate, to be determined, distribution channel. The first product is planned for Q4 2022 and beyond.
Can the products being developed at LFR be distributed through the existing marketing structure already in place at STEK?
Yes. Additional opportunities for distribution will be determined to leverage the R & D talent of LFR.
At what point, or when, will you advise investors of the financial details of the acquisition?
After more progress has been made in the due diligence process.
STEK revenues have remained steady over the past four quarters. What plans are in place that may ramp up sales of your existing product line, and has the IBP network grown in 2022?
Acquisition of LFR and their R & D capabilities will be the driving force for new product introductions. The first is planned for Q4 2022. The summer months are typically slower in the network marketing business. Stemtech launched a new marketing program in January 2022 which continues to promote and reach more people. Existing leaders are reaching out to other industry leaders who are disenchanted with their current companies, intending to invite them to join Stemtech. We are going live with the deployment of the VERB Technology mobile application being called “Stemtech Advance Office”, making this very powerful recruiting, ordering, training and live video streaming platform tool available to all existing Independent Business Partners (IBPs).
The Stemtech Life Sciences Advisory Board was joined by Professor Dr. Bankole A. Johnson, a world renowned expert in medicine, psychiatry and business.
Can you describe your future vision for your company?
Stemtech will make available again leading-edge technology products in the stem cell nutrition and beyond products which will be industry disrupters. In addition, Stemtech plans to open marketing and distribution channels in on-line and possibly brick and mortar sales. Further, there is a desire to also elevate the product offerings into a pharma-level availability. Stemtech will focus on expansion of the existing markets as well as international growth in new markets.
Thank you,
The Traders News Team
***The owners and operators of this website have NOT been compensated in any way for conducting or distributing this interview. Furthermore, we do not hold any form of equity in the publicly traded company/companies mentioned above***
Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails.
The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Editor@TradersNewsSource.com
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice.
All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.
TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.
